Clinical characteristics in 545 patients with severe asthma on biological treatment during the COVID-19 outbreak
Authors:
- Manuel Jorge RialMRManuel Jorge Rial
- Marcela ValverdeMVMarcela Valverde
- Victoria del PozoVPVictoria del Pozo
- Francisco Javier González-BarcalaFrancisco Javier González-Barcala
- Carlos Martínez-RiveraCMCarlos Martínez-Rivera
- Xavier MuñozXMXavier Muñoz
- José María OlaguibelJOJosé María Olaguibel
- Vicente PlazaVPVicente Plaza
- Elena CurtoECElena Curto
- Santiago QuirceSQSantiago Quirce
- Pilar BarrancoPBPilar Barranco
- Javier Domínguez-OrtegaJDJavier Domínguez-Ortega
- 1 January 2021
- journal article
- letter
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 9 (1) , 487-489.e1
Abstract
No abstract availableFunding Information
- Chiesi España
- GlaxoSmithKline España
- Novartis
- AstraZeneca España
This publication has 7 references indexed in Scilit:
- Prevalence, Characteristics, and Outcome of Asthmatic Patients With Type 2 Diseases in Hospitalized Patients With COVID-19 in Madrid, SpainJournal of Investigational Allergology and Clinical Immunology, 2020
- Early experiences of SARS-CoV-2 infection in severe asthmatics receiving biologic therapyThe Journal of Allergy and Clinical Immunology: In Practice, 2020
- Prevalence and characterization of asthma in hospitalized and nonhospitalized patients with COVID-19Journal of Allergy and Clinical Immunology, 2020
- Does asthma affect morbidity or severity of COVID-19?Journal of Allergy and Clinical Immunology, 2020
- Type 2 inflammation modulates ACE2 and TMPRSS2 in airway epithelial cellsJournal of Allergy and Clinical Immunology, 2020
- Does asthma make COVID-19 worse?Nature Reviews Immunology, 2020
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, ChinaThe Lancet, 2020